NVS 241220 105.00P (NVS241220P105000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

NVS241220P105000

Watchlist

6.99
+0.67+10.60%

15min DelayClose Dec 13 15:59 ET

6.99High6.99Low

Intraday

5D
Daily

News

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
BenzingaDec 13 12:15 ET
Swiss Equities an Overweight Pick Next Year -- Market Talk
WSJDec 13 11:36 ET
Top Gap Ups and Downs on Wednesday: MLI, MSTR, GSK and More
Moomoo NewsDec 11 18:00 ET · Markets
TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating, Announces Target Price $125
Moomoo NewsDec 11 16:31 ET · Ratings
Monte Rosa Closes Global License Agreement With Novartis
MT NewswiresDec 11 07:45 ET
Barclays Sticks to Its Sell Rating for Novartis AG (NOVN)
TipRanksDec 11 01:25 ET · Ratings

Comments

Asherboy88

Dec 11 08:09

$Novartis AG (NVS.US)$ what is happening ?? keeps going down

Movers and Shakers

Nov 21 07:11

Columns Today's Pre-Market Movers and Top Ratings | MSTR, NVDA, SNOW, PANW and More

Morning Movers
Gapping up
$Deere (DE.US)$ 's stock rose by 1.6% following their announcement of fourth-quarter earnings that surpassed analyst forecasts, despite substantial market hurdles.
Cryptocurrency-related stocks experienced a widespread surge. $MicroStrategy (MSTR.US)$ saw a significant increase, jumping over 13%, while $MARA Holdings (MARA.US)$ climbed more than 11%.
$Snowflake (SNOW.US)$ 's shares surged 23.3% as ...

Bitcoin breaks the $100,000 again: How high could it go?

10xStockPicks

Nov 15 08:23

ESPR Will Propel Higher, Events This Weekend & Analyst Event Next Week, Stock Price

This $2 Stock Remains Deeply Undervalued, Profitable in 2025, Offers 10x Upside within 20 Months
Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable. Fund that owns $Viking Therapeutics (VKTX.US)$ since 2022 below $10 a share is also investing in ESPR and expects the company will be a block buster.
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esper...

+18

thz stock ful of sht

Nov 15 01:20

DOWN

$Eli Lilly and Co (LLY.US)$ $Novo-Nordisk A/S (NVO.US)$ $Johnson & Johnson (JNJ.US)$ $AbbVie (ABBV.US)$ $Merck & Co (MRK.US)$ $ROCHE HOLDING AG (RHHBY.US)$ $Novartis AG (NVS.US)$ $AstraZeneca (AZN.US)$ $Amgen (AMGN.US)$ $Pfizer (PFE.US)$

10xStockPicks

Nov 8 08:28

This $2 Stock Remains Deeply Undervalued, Profitable in 2025, Offers 10x Upside within 20 Months

Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable. Fund that owns $Viking Therapeutics (VKTX.US)$ since 2022 below $10 a share is also investing in ESPR and expects the company will be a block buster.
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary...

+18